Evidence overview
5-HTP
5-HTP (5-hydroxytryptophan) is a serotonin precursor extracted from Griffonia simplicifolia seeds, marketed primarily for depression, anxiety, sleep, appetite regulation, and migraine. The clinical research base is small and methodologically limited - far smaller than the consumer market would suggest - and a long-standing safety concern (eosinophilia-myalgia syndrome from a related precursor) has shaped how the supplement is regulated and discussed.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Intermediate compound in the body's biosynthesis of serotonin from the essential amino acid tryptophan....
Study coverage
Study coverage by goal
PubMed counts for 5-HTP grouped by the goal each study targets.
Evidence overview is temporarily unavailable for 5-HTP.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
5-HTP (5-hydroxytryptophan) is a serotonin precursor that has been studied as a supplement for depression, anxiety, sleep disorders, appetite suppression and weight management, and migraine prevention. The compound is commercially extracted from the seeds of the African plant Griffonia simplicifolia and bypasses tryptophan's rate-limiting hydroxylation step in serotonin synthesis, which is the conceptual rationale for using it instead of tryptophan or other precursors. The supplement is sold as standalone 5-HTP and in combination products with cofactors like vitamin B6 and L-theanine.
The outcome dimensions covered most heavily are depression (the most-studied indication and the focus of the foundational Cochrane review), anxiety, sleep disorders (where 5-HTP has been studied as part of the broader serotonin-to-melatonin biosynthetic pathway), appetite and weight management, and migraine prevention. The depression literature has been characterized by methodological limitations across many trials, which the Cochrane synthesis explicitly notes. Smaller research streams cover fibromyalgia, panic disorder, and serotonin-deficiency hypotheses in various conditions.
Demographically, the literature concentrates on adults with mild-to-moderate depression or anxiety, with smaller research streams in patients with sleep complaints and overweight populations. A major historical issue shapes the 5-HTP literature: in 1989, an outbreak of eosinophilia-myalgia syndrome (EMS) was associated with a contaminated L-tryptophan supplement, and trace contamination concerns have continued to affect both L-tryptophan and 5-HTP regulation, manufacturing, and trial enrollment. This pharmacovigilance history is essential context for how the supplement is currently positioned and regulated.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
5-HTP has a non-trivial safety profile that warrants careful framing. The most-common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and abdominal cramping. The major historical safety concern is eosinophilia-myalgia syndrome (EMS), a serious connective-tissue disorder linked to a contaminated L-tryptophan supplement in 1989. While 5-HTP itself has not been definitively linked, trace contamination with 'Peak X' markers has been reported in some 5-HTP products and remains a manufacturing-quality concern. Serotonin syndrome is a serious theoretical concern when 5-HTP is combined with serotonergic medications: SSRIs, SNRIs, MAOIs, tramadol, dextromethorphan, and St. John's Wort. People taking any serotonergic medication should not supplement with 5-HTP without medical supervision. Pregnancy and breastfeeding safety is not established.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Foundations
Foundation of the evidence base
A few studies the field anchors on. Not the full picture, just the starting points.
Cochrane systematic review on tryptophan and 5-HTP for depression - the field's reference document for 5-HTP's primary established use, despite the supplement's relatively small total evidence base. Explicitly notes the methodological limitations across the underlying trial literature, which still shapes how the field positions 5-HTP today.
View on PubMed
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the 5-HTP literature at a general level. It does not address whether 5-HTP is appropriate for your specific situation (especially if you take any serotonergic medication, which is far more common than most users realize), what dose to use given the small evidence base, which product or manufacturer to choose (contamination concerns make brand selection unusually important for this supplement), or how 5-HTP interacts with your medications. Drug interactions with antidepressants are the single most-consequential safety question for 5-HTP, which makes the personalized report particularly useful here.
Personalized to you
Get a personalized 5-HTP report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on 5-HTP materially updates. No account required.